

**WHO Prequalification of In Vitro Diagnostics
PUBLIC REPORT**

**Product: Determine Syphilis TP
WHO reference number: PQDx 0485-013-00**

Determine Syphilis TP with product codes 7D2452, 7D2453 and 7D2453SET, manufactured by Abbott Diagnostics Medical Co., Ltd., Rest of World regulatory version, was accepted for the WHO list of prequalified in vitro diagnostics and was listed on 22 December 2022.

Summary of WHO prequalification assessment for Determine Syphilis TP

	Date	Outcome
Prequalification listing	22 December 2022	listed
Dossier assessment	29 November 2022	MR
Site inspection(s) of the quality management system	26-27 November 2018	MR
Product performance evaluation	Quarter 1 2021	MR

MR: Meets Requirements

Intended use

According to the claim of intended use from Abbott Diagnostics Medical Co., Ltd, “*Determine Syphilis TP is an in vitro, visually read, qualitative immunoassay for the detection of antibodies to Treponema pallidum, which is the bacteria that causes syphilis infection, in human capillary and venous whole blood, plasma or serum. The test is intended as an aid to detect antibodies to Treponema pallidum from infected individuals. The test is for professional use only. The device is not automated.*”

Assay description

According to the claim of assay description from Abbott Diagnostics Medical Co., Ltd, “*Syphilis is caused by infection with the bacterium Treponema pallidum which can be transmitted congenitally or by sexual contact. The disease can evolve into a latent phase in which syphilis is clinically inapparent. Serologic tests (nontreponemal specific and treponemal specific) are currently the primary method for syphilis diagnosis and management. Nontreponemal tests (VDRL, RPR, etc.) are generally used for screening, and treponemal tests (TPHA/TPPA, FTA-ABS, etc.) are used as confirmatory tests.*”

Test kit contents

Component	30 tests (product code 7D2452)	100 tests (product code 7D2453)	100 tests (product code 7D2453SET)
10 Tests/ card	3	10	10
Chase Buffer (7D2243) bottle of 2.5 mL	\	\	1
EDTA Capillary Tubes (7D2222) pack of 100	\	\	1
Blood Lancet (sterilized) (7D2233) box of 100	\	\	1
Instructions of use	1	1	1

Items required but not provided

- Disposable gloves
- Timing device
- Micropipette capable of delivering 50 µL (not required for fingerstick method)
- Alcohol swab and gauze pad
- Single-use sterile lancet (for fingerstick method)

Storage

The test kit must be stored at 2-30 °C.

Shelf-life upon manufacture

14 months.

Warnings/limitations

Please refer to the instructions for use attached to this public report.

Prioritization for prequalification

Based on the established eligibility criteria, Determine Syphilis TP was given priority for the WHO prequalification assessment.

Dossier assessment

Abbott Diagnostics Medical Co., Ltd. submitted a product dossier for Determine Syphilis TP as per the “*Instructions for compilation of a product dossier*” (PQDx_018 version 3). The information (data and documentation) submitted in the product dossier was reviewed by WHO staff and external technical experts (assessors) appointed by WHO.

The manufacturer's responses to the nonconformities found during dossier screening and assessment findings were accepted on 29 November 2022.

Commitments for prequalification

1. 7b1: Please provide details of the reference panels and the procedure for deeming equivalence from one lot of reference panels to the next.
2. 7c1: Please annotate Attachment 7c to specify what is meant by "score/signal score".
3. 8a: Please provide the CoA for a current lot of the positive control.
4. 10a: Please justify the reading time of 15-30 minutes.
5. 10b: Please clarify the Determine Syphilis TP reading time for the results presented in the clinical study report.
6. 10c: Please provide the information that will be included in the IFU that corresponds to the conclusions made in the clinical study report.
7. 18a: Please clarify the steps in the operation of the product that are undertaken by non-laboratory trained personnel.
8. 20a1: Please provide results for anti-TP positive specimens that contain endogenous interferents.
9. 20b1: Please clarify the acceptance criteria for the interfering substances studies.
10. 23c1: Please agree to modify the comment to be added to the IFU regarding the likelihood of a high-dose hook effect.
11. 24e1: Please provide evidence of drop-shock testing of the 7D2453SET configuration of the product.
12. 25a: Please provide details regarding the source and characterization of positive specimen used in the estimation of product shelf life and the relationship of its dilution series to other sensitivity specimens used for validation studies.
13. 27a1: Please provide the characterization of the specimens used in the tested performance panels at the epitope level.
14. 35a:
 - Please provide more information about the patients in the reported events and how it was determined that false negative results would be considered to cause no harm to a patient;
 - Please provide the SOP used to review the adverse events for reporting purposes at the time; and
 - Please provide the current SOP used for reporting adverse events if it has been updated.
15. Other IFU-related commitments:
 - Please include the target antibodies detected by the product, intended use population, and intended use setting in the IFU by 30 April 2023.
 - Please include a pen or pencil in the "Material Required But Not Provided" section of the IFU.
 - Please include specimen collection containers and instructions for obtaining serum and plasma in the IFU by 30 April 2023.

- Please include the instructions for users to store frozen specimens for 20 months and that a specimen is eligible for testing after only one freeze-thaw cycle.
- Please include the target detected or not detected in the interpretation of results section by 30 April 2023.
- Please update the clinical performance data in the IFU by 30 April 2023.

Based on the product dossier screening and assessment findings, the product dossier for Determine Syphilis TP meets WHO prequalification requirements.

Manufacturing site inspection

An inspection of Abbott Diagnostics Medical Co., Ltd, located at 357 Matsuhidai, Chiba-ken Matsudo-shi, 270-2214, Japan, was conducted from 26-27 November 2018. At the time of considering the product application for Prequalification, the Manufacturer of the product had a well-established quality management system and manufacturing practices in place that would support the manufacture of a product of consistent quality. Routine inspections of the Manufacturing site will be conducted with copies of the WHO Public Inspection Report (WHOPIR) published on the WHO Prequalification web page as per Resolution WHA57.14 of the World Health Assembly. Note that a WHOPIR reflects the information on the most current inspection performed at a manufacturing site for *in vitro* diagnostic products and gives a summary of the inspection findings.

Information on the most current inspection can be found at:

<https://extranet.who.int/pqweb/inspection-services/prequalification-reports/whopirs-vitro-diagnostics>

All published WHOPIRs are with the agreement of the manufacturer.

The manufacturer's responses to the nonconformities found at the time of the inspection were accepted on 24 May 2019.

Product performance evaluation

Determine Syphilis TP (Abbott Diagnostics Medical Co., Ltd) was evaluated by the National Serology Reference Laboratory (NRL) on behalf of WHO in the first quarter of 2021, according to protocol PQDx_326, version 2.0.

Clinical performance evaluation

In this limited laboratory-based evaluation of clinical performance characteristics, a panel of 570 plasma/serum specimens was used. The specimens were characterized using the following reference assays: LIAISON Treponema Screen CLIA (DiaSorin S.p.A), followed by

SERODIA TP-PA (Fujirebio) for detection of anti-TP antibodies; and BD Macro-Vue RPR Card Tests (Becton Dickinson) for detection of non-TP antibodies.

The clinical performance characteristics of Determine Syphilis TP for the detection of anti-TP antibodies were as follows:

Clinical performance characteristics in comparison with an agreed reference standard	
Sensitivity % (N=270)	100% (95% CI: 98.6-100)
Specificity % (N= 300)	98.7% (95%CI: 96.6-99.6)
Invalid rate % (N= 570)	0.4%
Inter-reader variability % (N= 570)	1.2%

Analytical performance evaluation

Analytical performance characteristics	
Sensitivity during seroconversion on 1 seroconversion panel in comparison with a benchmark assay (LIASION Treponema Screen CLIA)	Of a total of 9 specimens, 5 were detected by the assay under evaluation versus 4 specimens detected by the benchmark assay.
Analytical sensitivity on a performance panel (AccuSet Syphilis Performance Panel 0820-0300)	20 of the 20 specimens were correctly classified.
Analytical sensitivity on dilutions of the WHO International Standard for human syphilitic IgG and IgM panel (NIBSC code 05/132)	The lowest concentration detected by the assay was 0.023 IU/mL on both lot numbers.
Lot to lot variation on a dilution panel	Lot to lot variation was within +/- 1 two-fold dilutions for 9 dilution series and 2 two-fold dilutions for 1 dilution series.

Operational characteristics and ease of use

This assay does not require laboratory equipment and can be performed in laboratories with limited facilities or non-laboratory settings.

The assay was found easy to use by the operators performing the evaluation.

Key operational characteristics	
Specimen type and volume	50 µL of serum, EDTA plasma or EDTA whole blood (venous or capillary)
Number of steps*	For serum and plasma specimens: 1 step in total For whole blood specimens: 2 steps in total (add specimen, add Chase buffer) 1 step with precision pipetting (for serum/plasma/venous whole blood)
Time to result	15 minutes
Endpoint stability (interval)	15 minutes (the test can be read between 15 and 30 minutes after the addition of the specimen)
Internal QC	Yes, Reagent addition control

* Definition: each action required to obtain a result (excluding specimen collection, device preparation – opening the pouch), e.g. for RDTs: add specimen, add buffer (2 steps).


Based on these results, the performance evaluation for Determine Syphilis TP meets the WHO prequalification requirements.

Labelling

- 1. Labels**
- 2. Instructions for use**


1. Labels

1.1 Pouch label for product code 7D2452




Determine Syphilis TP for ROW 30 Test Pouch Label PN: 241886/R1	Pouch Size: 544mm(w) x 160mm(h) Label Artwork Size: 204mm(w) x 132mm(h)	White PMS 303 PMS 227
---	--	-------------------------------------

1.2 Pouch label for product code 7D2453



Determine Syphilis TP for ROW 100 Test Pouch Label	Pouch Size: 544mm(w) x 160mm(h)	White
PN: 241887/R1	Label Artwork Size: 204mm(w) x 132mm(h)	PMS 303 PMS 227


1.3 Box Artwork for product code 7D2453SET



241888/R1




Lot/Exp. Label





1.4 Label for the box

Determine™ Syphilis TP SET	Lot XXXXXXXXXXXX	Exp. 12AA-MM-DD
Contents:		
• Determine™ Syphilis TP(100 tests)	XXXXXXXXXXXX	12AA-MM-DD
• Chase Buffer(1 bottle)	XXXXXXXXXXXX	3BBB-MM-DD
• EDTA Capillary Tubes (100 EA)	XXXX	4CCC-MM-DD
• Blood Lancets(sterilized)(100 EA)	XXXXXX	5DDD-MM-DD

1.5 Chase buffer labels



Chase Buffer	 Black	PN: 1135904901
Box		
Size: (W)22mm x (L)44mm x (H)56mm		



1.6 Chase Buffer IFU



1156173202

REF 7D2243

DETERMINE™ CHASE BUFFER

Abbott

Key to symbols used/Používané symboly/Symbolforklaring/Erläuterung der verwendeten Symbole/
Πίνακας συμβόλων/Clave de los símbolos utilizados/Légende des symboles utilisés/
Legenda dei simboli utilizzati/Legenda dos símbolos utilizados/Symbolförlägning

2°C - 30°C Store at 2-30°C/Skladujte při teplotě 2-30°C/
Opbevares ved 2-30°C/Lagerung bei 2 bis 30°C/
Φύλασσεται στους 2-30°C/Almacenar a 2-30°C/
Conserver entre 2 et 30°C/Conservare a 2-30°C/
Conserver a 2°C-30°C/Förvaras vid 2-30°C

IVD For In Vitro Diagnostic Use/Pro diagnostické účely in vitro/
Til in vitro-diagnostisk brug/
Der Test ist nur für die In-vitro-Diagnos vorgesehen/
Για in vitro διαγνωστική χρήση/Para uso en diagnósticos in vitro/
Pour usage diagnostic in vitro/Per uso diagnostico In vitro/
Para uso em Diagnóstico In Vitro/För diagnostisk användning in vitro

CHASE BUFFER

Chase Buffer/Promývací pufr/
Chase-buffer/Laufpuffer/
Ρυθμιστικό διάλυμα σταθεροποίησης/
Tampón de detección/
Tampon de migration/
Tampon chase/Tampão de detecção/
Fixeringsbuffert

EN

Name and Intended Use

The Chase Buffer is for use with Determine™ products.

Refer to the package insert of the diagnostic assay for full procedure.
When adding Chase Buffer to the sample pad, hold the bottle vertically.
One bottle of Chase Buffer can be used for 100 tests.

For professional use only.

Contents

CHASE BUFFER 1 Bottle (2.5 mL) Chase Buffer prepared in phosphate buffer.
Preservatives: Antimicrobial Agents.

Storage Instruction

Recap and store the chase buffer at 2-30°C to avoid evaporation or spillage.

Advice Line

For further information, please contact your distributor,
or call Abbott Technical Specialists:

Africa: Tel: +27 10 500 9700
Email: arcis.techsupport@abbott.com
Russia & CIS: Tel: +44 161 483 9032
Email: arcis.techsupport@abbott.com
Asia Pacific: Tel: +61 7 3363 7100
Email: AP.TechSupport@abbott.com
Europe & Middle East: Tel: +44 161 483 9032
Email: EME.TechSupport@abbott.com
Latin America: Tel: +57 1 482 4033
Email: LA.TechSupport@Abbott.com

DA

Betegnelse og anvendelse

Chase-bufferen er til brug sammen med Determine™-produkter.

Se indlægssedlen til den diagnostiske analyse for den fulde procedure.
Hold flasken lodret, når Chase Buffer påføres prøvefeltet.
En flaske Chase Buffer kan bruges til 100 tests.
Kun til professionel brug.

Indhold

CHASE BUFFER 1 flaske (2,5 ml) chase-buffer i fosfatbuffer.
Konserveringsmiddel: antimikrobielle midler.

Opbevaringsinstruktion

Sæt hætte på og opbevar chase-bufferen ved 2-30°C for at undgå fordampning eller spild.

Rådgivning

Yderligere oplysninger fas ved at kontakte forhandleren eller ringe til Abbott Technical Specialists:
Afrika: Tel: +27 10 500 9700
Email: arcis.techsupport@abbott.com
Rusland og CIS: Tel: +44 161 483 9032
Email: arcis.techsupport@abbott.com
Asien/Stillehavet: Tel: +61 7 3363 7100
Email: AP.TechSupport@abbott.com
Europa og Mellomøsten: Tel: +44 161 483 9032
Email: EME.TechSupport@abbott.com
Latinamerika: Tel: +57 1 482 4033
Email: LA.TechSupport@Abbott.com

CZ

Název a použití

Promývací pufr je určen pro použití s výrobky Determine™.
Uplny postup naleznete v příbalovém listu diagnostické soupravy.
Při přidávání pufru do testovací kazety držte lahvičku ve vertikální poloze.
Jedna lahvička pufru vystačí na 100 testů.

Určeno pouze pro použití odborným zdravotnickým personálem.

Složení

CHASE BUFFER 1 lahvička (2,5 ml) - Promývací pufr připravený ve fosfátovém pufru.
Konzervační cindila: antimikrobiální látky.

Pokyny pro skladování

Promývací pufr znovu užavřete, aby nedošlo k jeho odpařování nebo vylití, a skladujte při teplotě 2-30°C.

Informační Linka

Pro další informace prosím kontaktujte svého distributora, nebo volejte Abbott Techničtí specialisté:

Afrika: Tel: +27 10 500 9700
Email: arcis.techsupport@abbott.com
Rusko a Společenství nezávislých států: Tel: +44 161 483 9032
Email: arcis.techsupport@abbott.com
Asie a Tichomoří: Tel: +61 7 3363 7100
Email: AP.TechSupport@abbott.com
Evropa a Střední Východ: Tel: +44 161 483 9032
Email: EME.TechSupport@abbott.com
Latinská Amerika: Tel: +57 1 482 4033
Email: LA.TechSupport@Abbott.com

DE

Produktbezeichnung und Verwendungszweck

Der Laufpuffer ist für die Verwendung mit Determine™ Produkten.
Informationen zur vollständigen Testdurchführung entnehmen Sie bitte der Packungsbeilage des diagnostischen Tests.

Halten Sie die Flasche Laufpuffer senkrecht, wenn Sie den Puffer auf das Proben-Pad geben.

Eine Flasche Laufpuffer kann für 100 Tests verwendet werden.

Nur für den professionellen Einsatz.

Inhalt

CHASE BUFFER 1 Fläschchen (2,5 ml) Laufpuffer, hergestellt in Phosphatpuffer.
Konservierungsmittel: Bakteriostatika.

Lagerungsvorschriften

Verschließen Sie den Laufpuffer wieder und lagern Sie ihn bei 2-30°C, um Verdunstung oder Verschütten zu vermeiden.


Infotelefon

Weitere Informationen erhalten Sie von Ihrem Vertreiber oder vom technischen Kundendienst von Abbott:

Afrika: Tel: +27 10 500 9700
Email: arcis.techsupport@abbott.com
Russland & GUS: Tel: +44 161 483 9032
Email: arcis.techsupport@abbott.com
Asien/Pazifikraum: Tel: +61 7 3363 7100
Email: arcis.techsupport@abbott.com
Europa & Mittlerer Naher Osten: Tel: +44 161 483 9032
Email: EME.TechSupport@abbott.com
Lateinamerika: Tel: +57 1 482 4033
Email: LA.TechSupport@Abbott.com

1.7 EDTA Capillary Tube label

EDTA Capillary Tubes	 Black	PN: 242047/R11
7D2222 Label		Date of Last Revision: 2021/02/05
Size: 3.5" x 3"		



1.8 Lancet label

6.4x4.4x7.5cm



2. Instructions for use¹

¹ English version of the IFU was the one that was assessed by WHO. It is the responsibility of the manufacturer to ensure correct translation into other languages.



DETERMINE™ SYPHILIS TP

Abbott

REF 7D2452/7D2453/
7D2453SET

October 2022
24xxx/R1

Key to symbols used/ Clave de los símbolos utilizados/ Légende des symboles utilisés/ Designação dos símbolos utilizados

	Store at 2-30°C/ Guardar a temperaturas entre 2 y 30°C/ Conserver entre 2-30°C/ Armazenar a 2-30°C
	Catalogue Number/ Número de catálogo/ Référence catalogue/ Nº de Catálogo
	Do not reuse/ No reutilizar/ Ne pas réutiliser/ Não reutilizar
	In Vitro Diagnostic Medical Device/ Dispositivo de diagnóstico médico in vitro/ Dispositif médical de diagnostic In Vitro/ Dispositivo Médico para Diagnóstico In Vitro
	Do not use if package is damaged/ No utilizar si el envase está roto/ Ne pas utiliser si l'emballage est endommagé/ Não utilizar caso a embalagem esteja danificada
	Keep away from sunlight/ No exponer a la luz solar/ Conserver à l'abri de la lumière du soleil/ Manter afastado da luz solar
	Contains Sufficient for 30 tests/ Contiene material suficiente para realizar 30 pruebas/ Permet de réaliser 30 tests/ Contém o suficiente para 30 testes
	Contains Sufficient for 100 tests/ Contiene material suficiente para realizar 100 pruebas/ Permet de réaliser 100 tests/ Contém o suficiente para 100 testes
	Consult instructions for use/ Consulte las instrucciones de uso/ Veuillez consulter le mode d'emploi/ Consulte as instruções de utilização

Advice Line

For further information, please contact your distributor, or call to one of the following Abbott Product Support Care Centers:

Region	Phone	E-Mail Address
Europe	+ (44) 161 483 9032	EME.TechSupport@abbott.com
Middle East	+ (965) 2202 2828	EME.TechSupport@abbott.com
Asia Pacific	+ (61) 7 3363 7711	AP.TechSupport@abbott.com
Africa	+ (27) 10 500 9700	arcis.techsupport@abbott.com
Russia & CIS	+ (7) 499 403 9512	arcis.techsupport@abbott.com
Latin America	+ (57) 601 482 4033	LA.TechSupport@abbott.com

Línea de consulta

Para mayor información, por favor contacte a su distribuidor, o llame a uno de los siguientes Centros de Soporte al Producto de Abbott:

Región	Teléfono	Dirección de correo electrónico
Europa	+ (44) 161 483 9032	EME.TechSupport@abbott.com
Medio Oriente	+ (965) 2202 2828	EME.TechSupport@abbott.com
Asia Pacífica	+ (61) 7 3363 7711	AP.TechSupport@abbott.com
Africa	+ (27) 10 500 9700	arcis.techsupport@abbott.com
Rusia, & CEI	+ (7) 499 403 9512	arcis.techsupport@abbott.com
América Latina	+ (57) 601 482 4033	LA.TechSupport@abbott.com

Ligne consacrée aux conseils

Pour de plus amples renseignements, s'il vous plaît contactez votre distributeur ou appelez l'un des centres de produits de support Abbott:

Region	Phone	E-Mail Address
Europe	+ (44) 161 483 9032	EME.TechSupport@abbott.com
Moyen-Orient	+ (965) 2202 2828	EME.TechSupport@abbott.com
Asie Pacifique	+ (61) 7 3363 7711	AP.TechSupport@abbott.com
Afrique	+ (27) 10 500 9700	arcis.techsupport@abbott.com
Russie & CEI	+ (7) 499 403 9512	arcis.techsupport@abbott.com
Amerique Latine	+ (57) 601 482 4033	LA.TechSupport@abbott.com

Linha de Aconselhamento

Para mais informações, por favor contacte o seu distribuidor, ou ligue para um dos seguintes Centros de Suporte ao Produto Abbott:

Região	Telefone	Direção do e-mail
Europa	+ (44) 161 483 9032	EME.TechSupport@abbott.com
Oriente Médio	+ (965) 2202 2828	EME.TechSupport@abbott.com
Ásia-Pacífico	+ (61) 7 3363 7711	AP.TechSupport@abbott.com
África	+ (27) 10 500 9700	arcis.techsupport@abbott.com
Rússia e CEI	+ (7) 499 403 9512	arcis.techsupport@abbott.com
América Latina	+ (57) 601 482 4033	LA.TechSupport@abbott.com

Whole Blood / Sangre Total / Sang Total / Sangue Total




Serum, Plasma / Suero, Plasma / Sérum, Plasma / Soro, Plasma

--	--

Positive / Positivo Positif / Positivo

Negative / Negativo Négatif / Negativo

Invalid / No válido Non valide / Inválido



This package insert must be read carefully prior to use. Package insert instructions must be followed accordingly. Reliability of assay results cannot be guaranteed if there are deviations from the instructions in this package insert.

NAME AND INTENDED USE

Determine™ Syphilis TP is an *in vitro*, visually read, qualitative immunoassay for the detection of antibodies to *Treponema pallidum*, which is the bacteria that causes syphilis infection, in human capillary and venous whole blood, plasma or serum. The test is intended as an aid to detect antibodies to *Treponema pallidum* from infected individuals. The test is for professional use only. The device is not automated.

SUMMARY AND EXPLANATION OF THE TEST

Syphilis is caused by infection with the bacterium *Treponema pallidum*¹ which can be transmitted congenitally or by sexual contact. The disease can evolve into a latent phase in which syphilis is clinically inapparent. Serologic tests (nontreponemal specific and treponemal specific) are currently the primary method for syphilis diagnosis and management. Nontreponemal tests (VDRL, RPR, etc.) are generally used for screening, and treponemal tests (TPHA/TPPA, FTA-ABS, etc.) are used as confirmatory tests.

BIOLOGICAL PRINCIPLES OF THE PROCEDURE

Determine Syphilis TP is an immunochromatographic test for the qualitative detection of antibodies to *Treponema pallidum* antigens. A Specimen is added to the sample pad. The specimen migrates through the conjugate pad and mixes with the *Treponema pallidum* antigen-selenium colloid conjugate. This mixture continues to migrate through the solid phase to the immobilized *Treponema pallidum* antigens at the patient window site. If antibodies to *Treponema pallidum* are present in the specimen, the antibodies bind to the *Treponema pallidum* antigen-selenium colloid and the *Treponema pallidum* antigen at the patient window, forming a red bar at the patient window site.

If antibodies to *Treponema pallidum* are not present, the *Treponema pallidum* antigen-selenium colloid flows past the patient window, and no red bar is formed at the patient window site.

To ensure assay validity, a procedural control bar is incorporated in the assay device at the control window.

CONTENTS

- **Determine Syphilis TP, 30 Tests (7D2452)**: 3 cards (10 tests/card) *Treponema pallidum* antigen coated.
- **Determine Syphilis TP, 100 Tests (7D2453)**: 10 cards (10 tests/card) *Treponema pallidum* antigen coated.
- **Determine Syphilis TP SET (7D2453SET)**: 100 Tests for testing whole blood samples
 - **Determine Syphilis TP (7D2453)**: 10 cards (10 tests/card) *Treponema pallidum* antigen coated.
 - Chase Buffer (7D2243) 1 bottle of 2.5ml
 - EDTA Capillary Tubes (7D2222) 1 pack for 100 tests
 - Blood Lancet (sterilized) (7D2233) 1 box for 100 tests

ACCESSORIES (required but not provided)

For testing Whole Blood samples

- 1 Bottle (2.5 mL) Chase Buffer (7D2243) containing phosphate buffered saline, preservative and antimicrobial agent.

For testing Whole Blood samples (fingerstick assay)

- EDTA Capillary Tubes (7D2222)

Materials Required But Not Provided

- Disposable gloves
- Timing device
- Micropipette capable of delivering 50 µL (not required for fingerstick method)
- Alcohol swab and gauze pad
- Single use sterile lancet (for fingerstick method)

WARNINGS AND PRECAUTIONS

For *In Vitro* Diagnostic Use.

For professional use only.

Safety data sheet available for professional user on request.

CAUTION

This product contains *Treponema pallidum* sourced potentially infectious components. Refer to the **CONTENTS** section of this package insert. No known test method can offer complete assurance that products derived from microorganisms will not transmit infection.

Therefore, it is recommended that the test device considered potentially infectious and handled with appropriate biosafety practices.^{2,3}

When handling specimens and reagents, use appropriate biosafety practices.

These precautions include, but are not limited to the following:

- Wear gloves.
- Do not pipette by mouth.
- Do not eat, drink, smoke, apply cosmetics, or handle contact lenses in areas where these materials are handled.
- Clean and disinfect all spills of specimens or reagents using suitable disinfectant, such as 0.5% sodium hypochlorite, or other suitable disinfectant.⁵
- Decontaminate and dispose of all specimens, used test strips, and other potentially contaminated materials in accordance with local regulations.⁵

STORAGE

Store Determine Syphilis TP Test Cards and Chase Buffer at 2-30°C until expiration date. After open the Chase Buffer, recap and store at 2-30°C to avoid evaporation or spillage.

- When handled and stored as directed, kit components are stable until the expiration date. Do not use kit components beyond expiration date.
- Immediately reseal all unused tests in the foil pouch containing the desiccant by pressing seal from end to end to close.
- Do not use devices that have become wet or the packaging has become damaged.

SPECIMEN COLLECTION

Serum, Plasma, and Whole Blood Collection by Venipuncture

Use EDTA collection tubes for whole blood and plasma specimens.

- Collect human whole blood by aseptic venipuncture
- To obtain serum, separate from the clot. To obtain plasma, separate from the packed cells. Separate specimens as soon as possible to avoid any hemolysis.

Whole Blood Collection by Fingerstick⁴ (See Fig.1)

Use EDTA Capillary Tubes (7D2222).

CAUTION: Glass capillaries may be damaged during transportation or when in use. Handle with care in order to avoid injury when removing from the package as well as during use and during disposal.

Before collecting a fingerstick specimen, place an EDTA capillary tube on a clean dry surface.

1. Choose the fingertip of the middle, ring, or index finger (whichever is the least callused) for adults and children older than one year. Warm the hand as needed with a warm, moist towel or warm water to increase blood flow.
2. Clean fingertip with alcohol; allow to air dry.
3. Position the hand palm-side up. Use a new lancet for each person. Place the lancet off-center on the fingertip. Firmly press the lancet against the finger and puncture the skin. Dispose the lancet in an appropriate biohazard sharps container.
4. Wipe away the first drop of blood with a sterile gauze pad.
5. Hold the finger lower than the elbow and apply gentle, intermittent pressure to the base of the punctured finger several times.
6. Touch the tip of the EDTA Capillary Tube to the drop of blood. Avoid air bubbles. Fill the tube with blood up to between the two marked lines (50 µL).



SPECIMEN STORAGE

- Store serum and plasma specimens at 2-8°C and run the test within 7 days of collection. If testing is delayed more than 7 days, freeze the specimen at -20°C or colder.
- Avoid repeated freeze/thaw cycles.
- If serum or plasma specimens show particulate matter or turbidity, centrifuge at 10,000g for 5 minutes at room temperature before sampling. Carefully take the 50 µL test sample from the supernatant. If a lipid layer is formed on the surface of the liquid, ensure that the sample is taken from the clear liquid below that layer.
- For whole blood collected by venipuncture, store at 2-8°C. Do not freeze whole blood specimens. Run the test within 7 days of collection.
- For whole blood collected by fingerstick, test immediately.

TEST PROCEDURE

Test at 15-40 °C

NOTE:

- To preserve the lot number which appears on the left side of the test card, remove individual test strips starting from the right side of the test card. The lot number and expiry date are not printed on the individual test strips.
- After removing the protective foil cover from each test strip, start the assay within 2 hours
- For serum or plasma, ensure thorough mixing of sample prior to use. For whole blood sample, mix well by gentle inversion of the tube immediately before testing.
- Running the test in high temperature/low humidity may affect the appearance of the patient bar. If the test strip is partially dried and difficult to read at 15 to 30 minutes, the test should be repeated using a new test strip and result read at 15 minutes.
- When the test strip is partially dried, it appears as mixed white spot and grayish area.
- If serum or plasma sample does not flow or shows abnormal flow, such as stopping in the middle of the window, centrifuge the specimen and repeat the test with a new test strip.

1. Remove the desired number of test strips from the 10 tests card by bending and tearing at the perforation.
2. Label or write the patient identification on the top white area of the device.
3. Remove the protective foil cover from each test.

- After removing the protective foil cover from each test strip, start the assay within 2 hours.

4. For serum or plasma samples:

- a. Apply 50 µL of sample (precision pipette) to the sample pad (marked by the arrow symbol).
- b. Wait a minimum of 15 minutes (up to 30 minutes) and read result.

5. For whole blood (venipuncture) samples:

- a. Apply 50 µL of sample (precision pipette) to the sample pad (marked by the arrow symbol).
- b. Wait one minute, then apply one drop of Chase Buffer to the sample pad, holding the bottle vertically
- c. Wait a minimum of 15 minutes (up to 30 minutes) and read result.

6. For whole blood (fingerstick) samples:

- a. Place the capillary tube containing the blood sample to the middle of the sample pad (marked by the arrow symbol) at an upright (vertical) position.

- b. Wait until blood is transferred from the capillary tube to the sample pad. Then immediately apply one drop of Chase Buffer to the sample pad, holding the bottle vertically.

Caution: do not lift the capillary tube from the sample pad before all the blood has been transferred - a bubble may form which will prevent the complete transfer of sample and invalidate the test. It may take more than one minute for full transfer of the sample.

c. Dispose the used capillary tube as biohazardous material according to local regulations.

d. Wait a minimum of 15 minutes (up to 30 minutes) and read result.

QUALITY CONTROL

To ensure assay validity, a procedural control is incorporated in the device and is labeled "Control". If the control bar does not turn red by assay completion, the test result is invalid. Repeat the test using a new test strip.


INTERPRETATION OF RESULTS

NOTES:

- Interpret any visible red bar (even very faint) in the window as a valid result.
- The test result is reactive even if the patient bar appears lighter or darker than the control bar.
- A test which gives very high background should be considered invalid.
- If an invalid test result occurs repeatedly, or for technical assistance, contact your local distributor or call Technical Support.

POSITIVE (Two Bars)

Red bars appear in both the control window (labeled "Control") and the patient window (labeled "Patient") of the strip. Any visible red bar in the patient window should be interpreted as positive.



Positive

NEGATIVE (One Bar)


One red bar appears in the control window of the strip (labeled "Control"), and no red bar appears in the patient window of the strip (labeled "Patient").



Negative

INVALID (No Control Bar)

If there is no red bar in the control window of the strip, and even if a red bar appears in the patient window of the strip, the result is invalid. Repeat the test using a new test strip.



Invalid

Negative

LIMITATIONS OF THE PROCEDURE

- No test provides absolute assurance that a sample does not contain low levels of antibodies to *Treponema pallidum*, such as those present at a very early stage of infection, or antibodies with low reactivity to the *Treponema pallidum* antigens. Therefore, a negative result at any time does not preclude the possibility of exposure to infection with syphilis.
- A non-reactive result at any time does not preclude the possibility of exposure to or infection with syphilis.
- Biotin treatment higher than 200mg per day may lead to decreased Control Bar intensity. Biotin concentrations up to 750 ng/mL in serum or plasma does not impact the Control Bar. There is no impact to the patient bar.

PERFORMANCE CHARACTERISTICS

SPECIFICITY AND SENSITIVITY

Serum specimens from 1133 cases of non-syphilis and 266 cases of syphilis from three clinical sites in Japan were tested by Determine Syphilis TP (Table I).

Table I
Specificity and Sensitivity of Determine™ Syphilis TP for Detection of Syphilis

	Population	Number of Specimens Tested	Determine™ Syphilis TP
Specificity (95%CI)	Non-syphilis	1133	99.74%(1130/1133) (99.23% - 99.95%)
Sensitivity (95%CI)	Syphilis	266	99.62%(265/266) (97.92% - 99.99%)

Whole blood specimens with paired serum and plasma from 79 cases of non-syphilis and 96 cases of syphilis from three clinical sites in Japan were tested with Determine Syphilis TP (Table II).

Table II

Specificity and Sensitivity of Determine™ Syphilis TP in Whole Blood and Paired Serum and Plasma Specimens

	Population	Number of Specimens Tested	Determine Syphilis TP		
			Whole Blood	Plasma	Serum
Specificity (95%CI)	Non-syphilis	79	98.73% (78/79) (93.15% - 99.97%)	98.73% (78/79) (93.15% - 99.97%)	98.73% (78/79) (93.15% - 99.97%)
Sensitivity (95%CI)	Syphilis	96	92.71% (89/96) (85.55% - 97.02%)	97.92% (94/96) (92.68% - 99.75%)	98.96% (95/96) (94.33% - 99.97%)

Cross reactivity and endogenous Interference

Determine Syphilis TP was evaluated for potential cross-reactivity and endogenous interference with 381 samples of patients which include infections other than syphilis, immunization and endogenous interfering substances.

Table III Cross Reactivity

Category	Sample group	Number of tested	Determine Syphilis TP	
			Positive	Negative
Viral infections	HIV	10	0	10
	Hepatitis A virus	5	0	5
	Hepatitis B virus (HBsAg)	16	0	16
	Hepatitis C virus	16	0	16
	Cytomegalovirus (CMV) IgG	17	0	17
	Cytomegalovirus (CMV) IgM	14	0	14
	EBV (Epstein-Barr virus) IgG	14	0	14
	EBV (Epstein-Barr virus) IgM	13	1**	12
Immunization	Herpes simplex virus (HSV)1/2	12	0	12
	Flu Vaccine Specimens	10	0	10
Interfering substances	Antiretroviral treated specimens	3	0	3
	Human anti mouse antibody (HAMA)	10	0	10
	Anti-nuclear antibody (ANA)	10	0	10
	Rheumatoid Factor (RF)	10	0	10
	Systemic lupus erythematosus (SLE)	5	0	5
	Triglyceride	5	0	5
	High IgM	5	0	5
	Cholesterol	5	0	5
	High total protein	4*	0	4*
	Multiparous pregnancy (MP)	197	2***	195
Total of cross reactivity and Interfering substances		381	3	378

*: 1 out of 5 high total protein samples was assay invalid due no red color of control bar.

**: 1 out of 13 EBV IgM samples was false positive.

***: 2 out of 197 showed false positive.

Total specificity in the potential cross reactivity and endogenous interference samples is 99.21% (95% CI 97.72-99.84%) representing no significant difference from clinical study.

Interference of exogenous substances

The interference of Bilirubin, Hemoglobin, Triglycerides, and EDTA was tested by spiking the interference materials into serum samples. 20 mg/dL Bilirubin, 500 mg/dL Hemoglobin, 1g/dL Triglyceride, and 200 mg/dL EDTA showed no interference.

The interference of relevant medicines were evaluated.

There is no interference for spiked positive and negative for the medicine in Table IV.

Table IV Interference

Type	Medicine	Concentration
Anti-parasitic medications	Eflornithine Metronidazole	16.8 mg/ml 0.123 mg/ml
Anti-bacterial medications	Amoxicillin Ciprofloxacin Azithromycin Levofloxacin	54.0 µg/ml 12.0 µg/ml 11.1 µg/ml 36.0 µg/ml
Anti-malarial medications	Mefloquine Quinine Pyrimethamine Primaquine	9.84 µg/ml 53.7 µg/ml 2.58 µg/ml 7.23 µg/ml
Anti-retroviral medication	Ritronavir	44.4 µg/ml
Anti-tuberculosis medication	Isoniazid (INH)	60.0 µg/ml
Antiviral	Ribavirin Entericavir Valganciclovir hydrochloride	11.0 µg/ml 24.6 ng/ml 21.4 µg/ml
Common over the counter analgesic medications	Aspirin Paracetamol	0.782 mg/ml 0.156 mg/ml

Analytical sensitivity

WHO International Standard (NIBSC code: 05/122) for Syphilis was tested with Determine Syphilis TP. Determine Syphilis TP detected 18.75mIU/ml.

Seroconversion Panel Testing

Commercially available seroconversion panels were evaluated.

Determine Syphilis TP could be detected before CE marked CLIA test and the same as RPR.

Table V Seroconversion Panel

Seroconversion Panel	Days from 1 st bleeding date	Non-treponema RPR test	CE marked CLIA test	Determine Syphilis TP
PSS901-01	0	-	-	-
PSS901-02	5	-	-	-
PSS901-03	10	-	-	-
PSS901-04	13	-	-	-
PSS901-05	31	+	-	+
PSS901-06	45	+	+	+
PSS901-07	48	+	+	+
PSS901-08	52	+	+	+
PSS901-09	59	+	+	+

Hook Effect

Determine Syphilis TP could detect 11 high titer positive samples as positive. 10 of the high titer positive samples had a TPPA titer of 40960 and the remaining 1 sample had a TPPA titer of 81920.

Reproducibility

Reproducibility of Determine Syphilis TP has been determined using in-house reference panels. There were no differences observed;

- within-run (replicates tested by one operator)
- day to day (five days)
- between run (three different test operators)
- between sites (three sites)
- lot-to-lot (3 different lots).

The manufacturing process produces different lot numbers for the kit and test cards; these lot numbers are traceable.

BIBLIOGRAPHY

1. Meyer JC. Laboratory Diagnosis of Syphilis. *Curr Probl Dermatol*. 1996;24:1-11.
2. World Health Organization. Laboratory Biosafety Manual Third edition. Geneva: World Health Organization, 2004.
3. Clinical and Laboratory Standards Institute Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline-Fourth Edition M29-A4 Vol. 34 No. 8 May 2014
4. Clinical and Laboratory Standards Institute. Procedures and Devices for the Collection of Diagnostic Capillary Blood Specimens; Approved Standard-Sixth Edition GP42-A6 Vol.28 No.25 September 2008
5. Clinical and Laboratory Standards Institute. Clinical Laboratory Waste Management; Approved Guideline –Third Edition. GP05-A3 Vol.31 No.3 January 2011

